Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Publikováno v:
European Journal of Endocrinology. 166:951-955
Background: Spontaneous hyperinsulinaemic hypoglycaemia following gastric bypass surgery (GBS) is increasingly recognised. However, its pathophysiology remains unclear. Some patients require pancreatectomy. Medical therapy with calcium channel blocke
Autor:
A. J., Van der Lely, I. Bernabeu, J. Cap, P. Caron, J. Marek, S. J. Neggers, P. B.i.r.m.a.n., COLAO, ANNAMARIA
Publikováno v:
European Journal of Endocrinology, 164(3), 325-333. Bioscientifica Ltd
ObjectiveTo evaluate the efficacy and safety of coadministered lanreotide Autogel (LA; 120 mg/month) and pegvisomant (40–120 mg/week) in acromegaly.DesignThis is a 28-week, multicenter, open-label, single-arm sequential study.MethodsPatients (n=92)
Publikováno v:
European Journal of Endocrinology. :473-480
OBJECTIVE: Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume 4 months, with serum GH levels 5.0 mU/l, Autogel was reduced to 60 mg, maintained at 90 mg, or increased to 120 mg res
Autor:
G Pagani, Alberto M Pedroncelli, Kris Poppe, Dominique Maiter, JJ Legros, D. Gianola, G Albani, Jean Mockel, Marie Bex, M. Montini, Mark Vandeweghe, Roger Abs, Pagani, J. Verhelst
Publikováno v:
Scopus-Elsevier
OBJECTIVE: Slow-release (SR) lanreotide is a long-acting somatostatin analog that has been developed in order to overcome the inconvenience of multiple daily subcutaneous injections of octreotide, required for metabolic control in acromegaly. Lanreot
Autor:
Jørgen Weeke, Hans Ørskov, Andreas Kaal, Steen Nielsen, Peter Marbach, Alberto M Pedroncelli, Ioana Lancranjan
Publikováno v:
European Journal of Endocrinology. :353-361
OBJECTIVE: Previous studies have indicated that antibody formation against octreotide is extremely rare. We examined the occurrence of octreotide antibody formation after treatment with three administration forms in large populations of patients with
Publikováno v:
European Journal of Endocrinology. :590-594
BACKGROUND: Octreotide treatment may be associated with gall stone development in up to 50% of patients with acromegaly. Two new sustained-release formulations of somatostatin analogue have been recently developed: lanreotide SR (Somatuline) and octr
Publikováno v:
European Journal of Endocrinology. 136:416-422
Octreotide, a potent synthetic somatostatin (SM) analogue, was recently evaluated and found to have a beneficial effect in thyroid eye disease (TED), mostly in those patients with a positive Octreoscan-111. Lanreotide (LRT; Somatuline-Ipsen), a new S
Autor:
Philippe Chanson
Publikováno v:
European Journal of Endocrinology. 143:573-575
Autor:
Wilhelmine Maschek, Robert Pichler
Publikováno v:
European Journal of Endocrinology. :179-180
Thyrotropin (TSH)-secreting adenoma is a rare entity and may be overlooked as a cause of clinical hyperthyroidism. Since the introduction of ultrasensitive assays for TSH and direct methods for free thyroid hormone measurements as first-line tests of